Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Feb 16, 06:15 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Yesterday


News

What Are the Key Growth Drivers for GlaxoSmithKline in 2019?

GSK GSK

MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development).

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Comparing Dividends and Tax Rates for MRK and GSK in 2019

GSK

MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?

GSK MRK

MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, February 14


News

MRK or GSK: Which Is Expected to Report Faster EPS Growth?

GSK

MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Credit Suisse Group Reiterates GBX 225 Price Target for Vodafone Group (VOD) – Fairfield Current

GSK GSK +2 more GSK GSK VOD VOD

Vodafone Group (LON:VOD) has been given a GBX 225 ($2.94) target price by investment analysts at Credit Suisse Group in a research report issued to clients and investors on Wednesday, January 23rd. UBS Group reiterated a “buy” rating and issued a GBX 230 ($3.01) price objective (down previously from GBX 230 ($3.01)) on shares of Vodafone Group in a report on Tuesday, November 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company’s stock. Vodafone Group currently has an average rating of “Buy” and a consensus target price of GBX 200.11 ($2.61).

Read Full Details

Topics:
  • Business
  • Financial
News

GSK Consumer: GSK Consumer Q3 profit rises 35% to Rs 221 crore

GSK

By PTI | Feb 14, 2019, 08.23 PM ISTView in App. The company's total income stood at Rs 1,241.07 crore, up 12.82 per cent, as against Rs 1,100.02 crore in the year-ago period, GSK Consumer Healthcare said in a BSE filing. "We have been witnessing healthy sustainable growth in our financial performance in the past few quarters. This growth is reflective of the unflinching trust that our consumers have in our products," GlaxoSmithKline Consumer Healthcare Managing Director Navneet Saluja said. On December 3, 2018, the company had announced divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc and the merger of GSK Consumer Healthcare with Hindustan Unilever Limited (HUL).

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, February 13


News

Global Nicotine Gum Market Report 2019-2023: British American Tobacco, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, and Novartis are Profiled

GSK GSK +1 more GSK GSK BATS

Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) -- The "Global Nicotine Gum Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. It is estimated that tobacco will cause more than 8 million deaths annually by 2030. According to the American Cancer Society, it takes about 8-10 quit attempts, while the Australian Cancer Council suggests that it takes 12-14 attempts to quit the habit of smoking. The emergence of e-cigarettes has considerably challenged the growth of the market.For the detailed list of factors that will drive and challenge the growth of the nicotine gum market during the 2019-2023, view this report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including GlaxoSmithKline and ITC Limited, the competitive environment is quite intense.

Read Full Details

Topics:
  • Business
  • Health

Monday, February 11


News

GSK: five reasons I’d buy the shares today

GSK GSK

The performance of GlaxoSmithKline (LSE: GSK) shares has been a little disappointing in recent years. For example, over the last decade, the stock has delivered a total return (share price gains plus dividends) of around 6.4%, which is significantly below the FTSE 100’s total return of 9.1% in that time. However, if you’re thinking about buying GSK shares, I wouldn’t let this past performance put you off. One reason I’m bullish on GSK right now is that back in December, the group announced that it had reached an agreement with Pfizer to combine their consumer health businesses. The combination will bring together two highly-complementary portfolios of trusted consumer health brands – including GSK’s Sensodyne, Aquafresh and Zovirax, and Pfizer’s Advil, Centrum and Caltrate – which will make it a market leader across pain relief, digestive health, and therapeutic oral health with sales of nearly £10bn and a market share of over 7%. Another reason I see appeal in the stock right now is the long-term growth story associated with the world’s ageing population. As people age, their demand for healthcare products and services tends to increase. As a healthcare specialist that owns an impressive portfolio of trusted consumer healthcare brands such as Panadol, Voltaren, and Fenbid (a painkiller sold in China), the group looks well placed to benefit as the global population continues to age.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, February 10


News

Buy-to-let returns are too low. I’d buy the GlaxoSmithKline share price every time

GSK GSK

Over the past few decades, buy-to-let as an asset class has created a tremendous amount of wealth for investors. However, more recently, it’s become harder to make money from renting than ever before. Additional layers of regulation, the withdrawal of certain tax benefits, and the introduction of new stamp duty charges for second home buyers, (up to 15% for homes over £1.5m) means that buy-to-let investing is no longer the sure thing it once was. Meanwhile, rental yields across the country have been falling and, although some markets still offer potential yields in the 5% to 8% range, when you include costs, returns aren’t as attractive. From an investment perspective, shares in Glaxo immediately looks to me to be a better buy than a rental property. For a start, buy-to-let is becoming an increasingly hot topic in the political world.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment

Friday, February 08


News

Have £1k to invest? I think the GSK share price could crush the FTSE 100 this year

GSK

FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) is often branded as a stock to buy and hold forever. But the shares have actually performed quite poorly for much of the last 25 years. These figures don’t include dividends, but data provided by Morningstar indicates that over the last 10 years, Glaxo stock has provided an average total return (share price + dividends) of just 6.3% per year. Ms Walmsley appears to share this view and has set a series of changes in motion that will see the consumer healthcare business combined with that of Pfizer. Cranswick’s share price fell by 13% on Thursday, as investors priced in the risk of slowing growth. However, the shares are still trading on around 17 times 2019 forecast earnings, with a 2% dividend yield.

Read Full Details

Topics:
  • Business
  • Health
  • Financial